AKTX
Akari Therapeutics PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.05M
P/E Ratio
0.00
EPS
$0.00
Beta
0.26
52W High
$63.20
52W Low
$3.25
50-Day MA
$8.56
200-Day MA
$24.65
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Akari Therapeutics PLC
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-12.08M |
| Operating Margin | 0.00% |
| Return on Equity | -68.40% |
| Return on Assets | -15.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $25.03 |
| Price-to-Book | 0.19 |
| Price-to-Sales (TTM) | 478368.50 |
| EV/Revenue | 400346.36 |
| EV/EBITDA | -0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.14M |
| Float | $55.15B |
| % Insiders | 24.56% |
| % Institutions | 9.75% |
Analyst Ratings
Consensus ($96.75 target)
1
Strong Buy2
BuyData last updated: 4/7/2026